Could This Under-the-Radar Healthcare Stock Set You Up for Life?

By Prosper Junior Bakiny – Apr 7, 2026 at 12:37PM ESTKey PointsKrystal Biotech has attractive prospects within its core market.The biotech could launch more products in the next few years.However, its long-term outlook remain highly uncertain. Krystal Biotech (KRYS +0.03%) has risen in prominence in recent years, with its shares gaining over 230% since 2021. Though it remains a mid-cap biotech with only a single marketed compound, it has an exciting pipeline and, if it executes its strategy effectively, may establish itself as a major drugmaker. However, stocks that generate life-changing returns do so through consistent performance over long periods -- think a few decades.

Does Krystal Biotech have what it takes to pull that off? Image source: Getty Images. Things look promising, but there are risks First, let's emphasize that Krystal Biotech has proven to be a fairly innovative company. In 2023, it received approval for Vyjuvek, a gene therapy indicated for the treatment of Dystrophic Epidermolysis Bullosa (DEB). This rare condition makes patients' skin extremely fragile, prone to blisters and wounds from otherwise minor friction. Vyjuvek was the first therapy approved by the U.S. Food and Drug Administration for DEB.

And Krystal Biotech is generating solid, growing sales from this product. In 2025, the company's revenue increased by 34% year over year to $389.1 million. What's equally impressive is that Krystal Biotech has turned profitable, a rare feat for biotechs of this size. Last year, the company's earnings per share came in at $6.84, more than double 2024's. Krystal Biotech became profitable by entering a DEB market with high unmet needs, where it launched the first approved product, granting it significant pricing power. There is still plenty of room to grow. The company is targeting a market of about 1,200 identified DEB patients in the U.S., and roughly 1,300 in Japan and some European nations where the medicine was approved last year. ExpandNASDAQ: KRYSKrystal BiotechToday's Change(0.03%) $0.09Current Price$264.07Key Data PointsMarket Cap$7.7BDay's Range$262.94 - $272.1852wk Range$122.80 - $298.30Volume27KAvg Vol299KGross Margin92.50% That's all well and good. To set investors up for life, though, Krystal Biotech will have to launch new products. The company's pipeline features several candidates across various rare diseases, including KB407 for cystic fibrosis, KB408 for alpha-1 antitrypsin deficiency lung disease, and several others. The best-case scenario for Krystal Biotech would go something like this. First, the company could continue generating steadily growing revenue and profits from its core DEB business. Then, the biotech would launch new products in other areas with high unmet needs, significantly boosting sales and profits. If it can protect its core franchises for the next decade or so, while developing newer therapies, it may perform well over the next 20 years. However, this long-term trajectory is extremely uncertain. And in the meantime, Krystal Biotech could face significant issues, including potential competition in the DEB market that could erode its pricing power, clinical or regulatory setbacks for other candidates, etc. So what's the verdict? Krystal Biotech is an innovative company that should ride its core therapeutic area for the next five years or so and could generate solid returns over this period. But the stock has more work to do before demonstrating its ability to perform well over several decades. For that, there are other, better-established healthcare stocks to consider. Read NextApr 9, 2026 •By Adria CiminoMeet the 2 Formerly Down-and-Out Stocks That Are Outperforming the S&P 500 This Year.

Are They Still a Buy?Apr 8, 2026 •By Prosper Junior BakinyIs This Healthcare Stock a Millionaire Maker?Apr 8, 2026 •By Adria CiminoWhich of These Healthcare Stocks Is More Likely to Be a Millionaire Maker?Apr 8, 2026 •By Eric VolkmanWhy Terns Pharmaceuticals Stock Rocked the Market in MarchApr 8, 2026 •By David Jagielski, CPAUnitedHealth Stock Jumps on Better-Than-Expected Medicare Advantage Rates. Here's Why the Rally Might Be Short-LivedApr 8, 2026 •By David Jagielski, CPA3 Absurdly Cheap Dividend Stocks to Buy in April 2026About the AuthorProsper Junior Bakiny is a contributing Motley Fool healthcare analyst covering biotechnology, pharmaceuticals, and healthcare stocks.

Before The Motley Fool, Prosper wrote about investing topics ranging from stock market news to private equity for various companies. He holds a master’s degree in corporate finance from the University of Maryland Global Campus.TMFPBakinyStocks MentionedKrystal BiotechNASDAQ: KRYS$264.08(+0.03%)+$0.09*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.